Project 1 Analyzing Tumor Microenvironment and Exploiting its Characteristics in Search of Optimizing Cancer Therapy Including Neutron Capture Therapy (R2P1)

概要

BACKGROUNDS AND PURPOSES: Human solid tu- mors contain moderately large fractions of quiescent (Q) tumor cells that are out of the cell cycle and stop cell divi- sion, but are viable compared with established experi- mental animal tumor cell lines. The presence of Q cells is probably due, in part, to hypoxia and the depletion of nu- trition in the tumor core, which is another consequence of poor vascular supply. As a result, Q cells are viable and clonogenic, but stop cell division. In general, radiation and many DNA-damaging chemotherapeutic agents kill prolif- erating (P) tumor cells more efficiently than Q tumor cells, resulting in many clonogenic Q cells remaining following radiotherapy or chemotherapy. Therefore, it is harder to control Q tumor cells than to control P tumor cells, and many post-radiotherapy recurrent tumors result partly from the regrowth of Q tumor cells that could not be killed by radiotherapy. Similarly, sufficient doses of drugs cannot be distributed into Q tumor cells mainly due to heteroge- neous and poor vascularity within solid tumors. Thus, one of the major causes of post-chemotherapy recurrent tumors is an insufficient dose distribution into the Q cell fractions.

　With regard to boron neutron capture therapy (BNCT), with 10B-compounds, boronophenylalanine-10B (BPA) in- creased the sensitivity of the total cells to a greater extent than mercaptoundecahydrododecaborate-10B (BSH). However, the sensitivity of Q cells treated with BPA was lower than that in BSH-treated Q cells. The difference in the sensitivity between the total and Q cells was greater with 10B-compounds, especially with BPA. These findings concerning the difference in sensitivity, including other re- covery and reoxygenation following neutron irradiation after 10B-compound administration were mainly based on the fact that it is difficult to deliver a therapeutic amount of 10B from 10B-carriers throughout the target tumors, es- pecially into intratumor hypoxic cells with low uptake ca-pacities.

　Hypoxia is suggested to enhance metastasis by increas- ing genetic instability. Acute, but not chronic, hypoxia was reported to increase the number of macroscopic metastases in mouse lungs. We recently reported the significance of the injection of an acute hypoxia-releasing agent, nicotin- amide, into tumor- bearing mice as a combined treatment with -ray irradiation in terms of repressing lung metasta- sis. As the delivered total dose increased with irradiation, the number of macroscopic lung metastases decreased re- flecting the decrease in the number of clonogenically via- ble tumor cells in the primary tumor. The metastasis-re- pressing effect achieved through a reduction in the number of clonogenic tumor cells by irradiation is much greater than that achieved by releasing tumor cells from acute hy- poxia. On the other hand, more 10B from BPA than from BSH could be distributed into the acute hypoxia-rich total tumor cell population, resulting in a greater decrease in the number of highly clonogenic P tumor cells with BPA- BNCT than with BSH-BNCT and with neutron beam irra- diation only. BPA-BNCT rather than BSH-BNCT has some potential to decrease the number of lung metastases, and an acute hypoxia-releasing treatment such as the ad- ministration of nicotinamide, bevacizumab, wortmannin or thalidomide may be promising for reducing numbers of lung metastases. Consequently, BPA-BNCT in combina- tion with the treatment using these agents may show a little more potential to reduce the number of metastases. Now, it has been elucidated that control of the chronic hypoxia- rich Q cell population in the primary solid tumor has the potential to impact the control of local tumors as a whole, and that control of the acute hypoxia-rich total tumor cell population in the primary solid tumor has the potential to impact the control of lung metastases.

　The aim of this research project is focused on clarify- ing and analyzing the characteristics of intratumor micro- environment including hypoxia within malignant solid tu- mors and optimizing cancer therapeutic modalities, espe- cially radiotherapy including BNCT in the use of newly- developed 10B-carriers based on the revealed findings on intratumor microenvironmental characteristics.

この論文で使われている画像